zynerba
pharmaceuticals
present
two
upcoming
virtual
investor
conferences
devon
globe
newswire
zynerba
pharmaceuticals
nasdaq
zyne
leader
innovative
transdermal
cannabinoid
therapies
rare
neuropsychiatric
disorders
today
announced
zynerba
chief
executive
officer
armando
anido
participate
two
upcoming
virtual
investor
conferences
anido
present
company
overview
hc
wainwright
virtual
annual
healthcare
conference
monday
september
edt
also
present
cantor
global
virtual
healthcare
conference
tuesday
september
edt
meetings
held
virtually
live
webcasts
presentations
accessible
investor
relations
page
http
zynerba
pharmaceuticals
zynerba
pharmaceuticals
leader
transdermal
cannabinoid
therapies
rare
neuropsychiatric
disorders
committed
improving
lives
patients
families
living
severe
chronic
health
conditions
including
fragile
x
syndrome
autism
spectrum
disorder
deletion
syndrome
heterogeneous
group
rare
epilepsies
known
developmental
epileptic
encephalopathies
learn
follow
us
twitter
zynerbapharma
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
may
cases
use
terms
predicts
believes
potential
proposed
continue
estimates
anticipates
expects
plans
intends
may
could
might
words
convey
uncertainty
future
events
outcomes
identify
statements
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
company
current
expectations
risks
described
company
periodic
reports
including
annual
report
form
quarterly
reports
form
current
reports
form
filed
furnished
securities
exchange
commission
available
statements
company
makes
press
release
speak
date
press
release
company
assumes
obligation
update
statements
whether
result
new
information
future
events
otherwise
date
press
release
